Applied Molecular Transport Reports Third Quarter 2023 Financial Results
November 09, 2023 16:01 ET
|
Applied Molecular Transport Inc.
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE...
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
August 14, 2023 16:01 ET
|
Applied Molecular Transport Inc.
Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14,...
Applied Molecular Transport Reports First Quarter 2023 Financial Results
May 11, 2023 16:05 ET
|
Applied Molecular Transport Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first...
Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives
March 27, 2023 16:01 ET
|
Applied Molecular Transport Inc.
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s...
Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 09, 2023 16:05 ET
|
Applied Molecular Transport Inc.
Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no FDA-approved products Evaluating next steps for the company's second clinical asset,...
Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
March 03, 2023 08:00 ET
|
Applied Molecular Transport Inc.
New positive data demonstrate oral AMT-101’s gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design Translational analysis reveals IL-10 biological...
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
December 22, 2022 17:30 ET
|
Applied Molecular Transport Inc.
– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s...
Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis
November 10, 2022 08:00 ET
|
Applied Molecular Transport Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan...
Applied Molecular Transport to Present at Upcoming November Investor Conferences
November 08, 2022 08:00 ET
|
Applied Molecular Transport Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at...
Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 07, 2022 16:01 ET
|
Applied Molecular Transport Inc.
Company held end of Phase 2 meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products Anticipate Phase 2...